Document is current
Any future updates will be listed below
-
Authors
Sklerov, Miriam https://orcid.org/0000-0001-6031-4763
Shih, Chia-Hao
Browner, Nina
Palma, Jose-Alberto
Styner, Martin
Dayan, Eran
- License Information
-
More Information
Article History
Received: 24 November 2019
Accepted: 7 February 2020
First Online: 20 February 2020
Compliance with ethical standards
:
: Jose-Alberto Palma has been an advisory board member/consultant for Lundbeck, Biogen, PTC Therapeutics, and Dr. Reddy’s Laboratories. He receives research funding from the NINDS, the Michael J. Fox Foundation, and the Familial Dysautonomia Foundation. He is the principal investigator in clinical trials funded by Biohaven and Theravance. Nina Browner has received Parkinson Foundation speakers and travel fees. Miriam Sklerov, Chia-Hao Shih, Styner, and Eran Dayan report no disclosures. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
: Data used in this manuscript were obtained from the Parkinson’s Progression Markers Initiative (PPMI), a publicly available dataset. All study procedures were approved by the appropriate ethics committees at each participating site. All participants gave informed consent prior to inclusion in PPMI. For up-to-date information on the study, visit .
